Compare Build A Bear Workshop Inc (BBW) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Build A Bear Workshop Inc vs Novartis AG — how do they compare? Build A Bear Workshop Inc trades at $32.95 (market cap $412.61M), while Novartis AG trades at $150.44 (market cap $288.65B). The key difference: Novartis AG is far larger — about 699.6× Build A Bear Workshop Inc's market cap, and Novartis AG pays the higher dividend (3.15%). Which is the better fit depends on your goals.
| BBW | NVS | |
|---|---|---|
Market Cap | $412.61M | $288.65B |
Sector | Consumer Cyclical | Health |
52-Week High | $75.85 | $168.62 |
52-Week Low | $29.84 | $113.50 |
Enterprise Value | $512.05M | $328.67B |
Dividend Yield | 2.8% | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novartis (NVS) trades at $153.37, down 0.44% today, with a bullish technical signal from moving averages. The company reported $56.67B revenue in 2025 with strong profitability margins (net income margin 23.92%) and recently expanded its oncology pipeline through acquisitions like Myricx Bio. Earnings have been mixed, with a miss in Q1 2026 but a beat in Q4 2025.
Outlook remains stable with revenue projections near $56.6B for 2026, though debt-to-asset ratio has risen to 30.26%. Risks include pipeline execution and competitive pressures. Analysts show cautious optimism with 68% hold ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Build A Bear Workshop Inc
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
